Skip to main content
Pherecydes Pharma logo

Pherecydes Pharma — Investor Relations & Filings

Ticker · ALPHE ISIN · FR0011651694 LEI · 894500LYT3UUN58X3I68 PA Professional, scientific and technical activities
Open in API
Filings indexed 146 across all filing types
Latest filing 2021-03-22 Report Publication Anno…
Country FR France
Listing PA ALPHE

About Pherecydes Pharma

https://www.pherecydes-pharma.com/en/

Pherecydes Pharma is a clinical-stage biotechnology company specializing in the research and development of phage therapy to combat antibiotic-resistant bacterial infections. The company develops targeted treatments using bacteriophages, which are naturally occurring viruses that specifically infect and destroy bacteria. Its therapeutic approach focuses on providing personalized solutions for severe infections, particularly those caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company utilizes a proprietary phage bank and a diagnostic tool to determine the most effective phages for each patient's specific bacterial strain. In 2023, Pherecydes Pharma merged with Erytech to form Phaxiam Therapeutics, combining expertise to advance phage therapy as a mainstream anti-infective solution.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 99% confidence The document is titled "Pherecydes Pharma annonce son calendrier financier 2021" (Pherecydes Pharma announces its 2021 financial calendar). It explicitly lists future dates for key financial events: Annual Results 2020, General Meeting, and 1st Half 2021 Results. This document is an announcement detailing *when* future reports and meetings will occur, rather than being the report itself (like 10-K or IR) or the transcript of a call (CT). Since it announces the publication schedule for reports, it fits best under Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because RPA is more specific for scheduling announcements.
2021-03-22 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release dated March 15, 2021, announcing that Pherecydes Pharma's project was featured in the European Commission's CORDIS magazine. It discusses R&D funding, GMP production, and future clinical trials. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). It is an announcement about company activities and external recognition, which fits best under the general category for regulatory announcements or news releases that don't fit specific financial reporting codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general corporate news announcement that isn't a specific financial report or management change.
2021-03-15 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated March 15, 2021, announcing that Pherecydes Pharma's PhagoPROD project, funded by the European Commission, is featured in the CORDIS magazine. It discusses R&D funding, production processes (BPF), and clinical trials. This type of announcement, highlighting a specific company achievement, project update, or external recognition, does not fit neatly into the core financial reporting categories (10-K, IR, ER, MRQ). It is a general corporate announcement. Since it is not a formal regulatory filing like a Director's Dealing (DIRS) or a Dividend Notice (DIV), and it's not a transcript (CT) or a presentation (IP), the most appropriate fallback category for a general, non-standard corporate update or press release is Regulatory Filings (RNS), which serves as the miscellaneous category for announcements that don't fit elsewhere.
2021-03-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release dated February 16, 2021, announcing that the USPTO granted two new patents to Pherecydes Pharma for its phages. The content focuses entirely on intellectual property (patents) protection and expansion of geographical coverage for these patents. This type of announcement, which details specific legal/IP achievements rather than financial results, management changes, or general operational updates, fits best under a category related to specific corporate actions or legal matters. Since it is not a standard financial report (10-K, IR, ER), a management change (MANG), or a director's dealing (DIRS), and it specifically concerns intellectual property rights, it is most closely related to legal/regulatory updates. However, none of the provided codes perfectly capture 'Patent Grant Announcement'. Given the options, 'LTR' (Legal Proceedings Report) is too focused on litigation, and 'RNS' (Regulatory Filings) is a fallback. Since the core subject is the protection of intellectual property, which is a key aspect of corporate strategy and legal standing, and it is presented as a formal announcement, I will evaluate if it fits better elsewhere. It is not a financing event (CAP), nor a general governance report (CGR). Because it is a specific, non-financial, non-management corporate announcement concerning legal rights (patents), and it is not a report itself (it's an announcement), the most appropriate general category for specific, non-financial corporate news that isn't covered elsewhere is 'RNS' (Regulatory Filings/General Announcement). However, if we interpret 'LTR' broadly as covering significant legal/statutory rights updates, it could fit, but 'LTR' usually implies litigation. Given the strong focus on IP protection, and lacking a specific 'IP' or 'Patent' code, 'RNS' serves as the best general regulatory/corporate announcement category for this specific news item, as it is a formal public disclosure of a significant corporate asset update. Upon re-reviewing the definitions, 'IP' (Investor Presentation) is incorrect. Since this is a formal announcement about a legal asset (patent), and it is not a standard financial filing, 'RNS' is the most suitable fallback for a specific corporate disclosure that doesn't fit the other narrow categories.
2021-02-16 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release dated February 16, 2021, announcing that Pherecydes Pharma has been granted two new patents by the USPTO for its anti-Pseudomonas Aeruginosa and anti-E. Coli phages. The content focuses entirely on intellectual property (patents) and its strategic implications, not on financial results, management changes, or general regulatory compliance filings (like 10-K or ER). While patent news is related to corporate activity, none of the specific filing types (AGM-R, 10-K, ER, MANG, etc.) directly cover a press release focused solely on patent grants. The closest related concept might be Intellectual Property (IP), but IP is not explicitly defined as a press release about patents. Given the options, this is a general corporate announcement that doesn't fit the specific financial or governance categories. Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it serves as the general category for miscellaneous regulatory/corporate announcements that don't fit elsewhere, although 'IP' would be ideal if it were an option for this type of news release.
2021-02-16 French
Acquisition ou cession des actions de l'émetteur / Information relative au contrat de liquidité
Transaction in Own Shares Classification · 98% confidence The document is a press release dated February 9, 2021, announcing the implementation of a liquidity contract with Portzamparc in the context of a share repurchase program ('programme de rachat d'actions'). It details the terms of this contract, including the financial means allocated (€200,000 in cash) and references the authorization from the Shareholders' General Meeting of December 24, 2020, for the share repurchase program. The core subject is the company's action regarding its own shares (repurchase/liquidity provision). This directly corresponds to the definition of 'Transaction in Own Shares' (POS), which covers share repurchase programs.
2021-02-09 French

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.